Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.



JMS CO.,LTD.

[Reference Translation]

February 28, 2025

Company name: JMS Co., Ltd.

Name of representative: Ryuji Katsura, President and Representative Director

(Securities code: 7702; Tokyo Stock Exchange

Contact: Jo Sueda, Executive Officer, Head of Corporate Affairs Division

(Telephone: +81-82-243-5844)

Contact site: https://www.jms.cc/english/contact/index.html

Announcement Regarding Launching Multifunctional Dialysis Machine "JMS Single Patient Dialysis Machine SD-X01".

~ Improved efficiency and safety of hemodialysis therapy~

HIROSHIMA, JAPAN – February 28, 2025- JMS Co., Ltd., (President: Ryuji Katsura, hereinafter called "JMS") today announced that it launched Multifunctional Dialysis Machine "JMS Single Patient Dialysis Machine SD-X01" (Hereinafter called "SD-X01").

[Background of development]

The number of patients with end-stage renal failure in Japan is estimated to be about 330,000, which majority are receiving hemodialysis therapy. In terms of the type of dialysis machine, there are two choices. Dialysis machine used under Central Dialysis Fluid Delivery System (CDDS), which centrally prepares and supplies dialysis fluid to each dialysis machine (hereinafter called "Dialysis machine for CDDS") and Dialysis machine including the function of preparing for dialysis fluid independently (herein after called "Single Patient Dialysis Machine"). Those choices are decided depending on the treatment environment or the scale of medical facility. Also, Single Patient Dialysis Machine is chosen when infection control is required or in case of emergency.

"SD-X01" achieves intuitive operability and high safety by leveraging our accumulated expertise in the development of Dialysis machine for CDDS and by inheriting its design concept.

[Features of SD-X01]

- 1. Intuitive operation reducing the burden of daily practices for hemodialysis operations
 - Improved visibility and operability by adopting large 15-inch touch panel.
 - Ergonomically designed for easy screen operation and simple setup of the blood tubing set.
- 2. Supporting safe and efficient dialysis therapy
 - Achieved smooth setup by automating preparation before dialysis starts.
 - Equipped with a function that automatically terminates dialysis therapy safely in the event of a power outage or emergency.
 - Streamlining management of treatment data by linking with our d information system "ERGOTRI®".



The large touchscreen features high visibility and an intuitive layout that separates the display and control zones for easy operation.



Through ergonomic design based on input from medical staff, a wide and flat surface for easy attachment of tubing sets is realized.

- 3. Providing more optimal hemodialysis therapy
 - Expand treatment options by supporting a variety of HDF* therapies.
 - Contribute to improving patients' quality of life (QOL)

JMS will continue to support safe, secure, and efficient medical care and contribute to improving patients' quality of life through the development and supply of products and services with the perspective of the medical field.

*Hemodiafiltration (HDF): A dialysis method that combines Hemodialysis (HD) and Hemofiltration (HF), incorporating the advantages of both techniques. It efficiently removes waste products, such as large molecular substances (e.g., low-molecular-weight proteins), from the blood.

[Reference Material]

Outline of products

| or products | |
|--------------------------------|-------------------------------------|
| Generic Name | Multifunctional Dialysis Machine |
| | Single Patient Dialysis Machine |
| Brand Name | JMS Single Patient Dialysis Machine |
| | SD-X01 |
| Medical Device Approval Number | 30600BZX00006000 |
| Manufacturer and Distributor | JMS Co., Ltd. |



The forward-looking statements in this release are based on judgments made in accordance with currently available information and are subject to various potential risks and uncertainties, including major changes in social conditions. Please note that this information is current as of the date of publication and is subject to change in the future.

Although it contains information on medical devices and pharmaceuticals, this information is intended for the press, shareholders, investors, and others, and is not intended to solicit customers or provide medical advice.

END